Profile | GDS2987 / GI_22547209-I |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 20.2 | 55 |
GSM215244 | HMVEC_vehicle_rep2 | 33.6 | 61 |
GSM215253 | HMVEC_vehicle_rep3 | 12.4 | 39 |
GSM215254 | HMVEC_atorvastatin_rep1 | 12.4 | 32 |
GSM215282 | HMVEC_atorvastatin_rep3 | 22.6 | 46 |
GSM215344 | HMVEC_atorvastatin_rep2 | 24.1 | 50 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 7.7 | 15 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 48.1 | 64 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 37 | 51 |
GSM215294 | HMVEC_SLx2119_rep1 | 14.8 | 47 |
GSM215295 | HMVEC_SLx2119_rep2 | 42.4 | 61 |
GSM215296 | HMVEC_SLx2119_rep3 | 49.5 | 61 |
GSM215297 | PASMC_vehicle_rep1 | 21.7 | 32 |
GSM215298 | PASMC_vehicle_rep2 | 21.5 | 32 |
GSM215310 | PASMC_vehicle_rep3 | 21.5 | 33 |
GSM215311 | PASMC_atorvastatin_rep1 | ||
GSM215312 | PASMC_atorvastatin_rep2 | 50 | 60 |
GSM215313 | PASMC_atorvastatin_rep3 | 38.5 | 50 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 56.7 | 64 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 20.3 | 37 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 22.4 | 36 |
GSM215327 | PASMC_SLx2119_rep1 | 25.6 | 41 |
GSM215328 | PASMC_SLx2119_rep2 | 4.1 | 8 |
GSM215329 | PASMC_SLx2119_rep3 | 23.2 | 41 |
GSM215330 | Fibroblasts_vehicle_rep1 | 16.3 | 36 |
GSM215331 | Fibroblasts_vehicle_rep2 | 24.8 | 54 |
GSM215332 | Fibroblasts_vehicle_rep3 | 10.4 | 33 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 39.3 | 65 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 5 | 14 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 15.5 | 45 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 9.4 | 30 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | ||
GSM215339 | Fibroblasts_SLx2119_rep1 | 16.8 | 44 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 3.2 | 9 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 24.3 | 51 |